Evidence-Based Medical Resource
Type 1 Diabetes
A Complete Guide
An autoimmune condition requiring lifelong management. This guide covers everything — from biology and diagnosis through cutting-edge technology and emerging therapies.
9 Million
People worldwide
Any age
Onset possible
5–10%
Of all diabetes cases
100+
Years since insulin
01 — What Is It?
An Autoimmune Condition
Type 1 diabetes (T1D) is a chronic autoimmune disease in which the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas's islets of Langerhans.
Without these beta cells, the body cannot produce insulin — the hormone essential for transporting glucose from the bloodstream into cells for energy. This leads to dangerously elevated blood glucose levels.
Unlike Type 2 diabetes, T1D is not caused by lifestyle factors. It is unpreventable with current knowledge and requires insulin replacement therapy from the moment of diagnosis for survival.a
The exact trigger for the autoimmune attack is not fully understood, but both genetic predisposition and environmental factors (e.g. viral infections) appear to play a role.
Genetic Susceptibility
Certain HLA gene variants (especially HLA-DR3/DR4) increase risk. A family history of T1D raises risk by 5–15%.
Environmental Trigger
A virus (e.g. enteroviruses), gut microbiome shifts, or other environmental factor may initiate the autoimmune process.
Immune System Attack
T-cells and autoantibodies (anti-GAD, anti-IA-2, anti-ZnT8) target and destroy beta cells over months to years.
Beta Cell Loss
Symptoms emerge once ~80–90% of beta cells are destroyed. Some residual function ("honeymoon phase") may persist briefly.
Clinical Diagnosis
Full dependence on exogenous insulin begins. Lifelong management is required.
02 — Recognising T1D
Symptoms & Warning Signs
Symptoms typically develop rapidly — over days to weeks. Recognising them early is critical to prevent diabetic ketoacidosis (DKA), a life-threatening complication.
Polyuria
Frequent, excessive urination — including overnight. The kidneys attempt to filter excess glucose from the blood, drawing large amounts of water with it.
Extreme Fatigue
Without insulin, cells are starved of energy despite high blood glucose. Profound, persistent tiredness is a hallmark early symptom.
Polydipsia
Extreme, unquenchable thirst resulting from the dehydration caused by excessive urination. Drinking large volumes doesn't resolve the feeling.
Blurred Vision
High blood sugar causes fluid shifts in the eye's lens, temporarily distorting vision. This usually resolves with glucose normalisation.
Unexplained Weight Loss
Despite normal or increased eating, rapid weight loss occurs as the body breaks down fat and muscle for energy due to lack of usable glucose.
Increased Hunger
Despite elevated blood glucose, cells cannot absorb it without insulin, leaving the body in a perpetual state of cellular "starvation."
Diabetic Ketoacidosis (DKA) — Medical Emergency
DKA is a life-threatening condition that can develop rapidly when T1D is undiagnosed or insulin is severely insufficient. It represents a medical emergency requiring immediate hospital treatment.
Nausea & Vomiting
Often severe abdominal pain
Fruity Breath
From acetone (ketones) on the breath
Deep, Laboured Breathing
Kussmaul respirations body expelling CO₂
Confusion / Drowsiness
Can progress to unconsciousness
Call 999 / 112 immediately if DKA is suspected. Do not wait.
03 — Diagnosis
How T1D is Diagnosed
Diagnosis involves blood tests to measure blood glucose and confirm the autoimmune nature of the disease. Early and accurate diagnosis is crucial.
Key Diagnostic Tests
Random Blood Glucose
≥11.1 mmol/L (200 mg/dL) with symptoms is diagnostic. Often the first test performed in an acute presentation.
Fasting Plasma Glucose
≥7.0 mmol/L (126 mg/dL) after at least 8 hours fasting confirms diabetes.
HbA1c
≥48 mmol/mol (6.5%) reflects average blood glucose over ~3 months. Used for confirmation and ongoing monitoring.
Autoantibody Testing
Positive anti-GAD, anti-IA-2, anti-ZnT8, or anti-ICA antibodies confirm the autoimmune aetiology and distinguish T1D from T2D.
C-Peptide
Low or undetectable C-peptide confirms severely reduced or absent endogenous insulin production — characteristic of T1D.
Staging of T1D
T1D is now recognised as progressing through defined stages before clinical symptoms appear, offering opportunities for earlier intervention.
STAGE 1
Presymptomatic — Autoimmunity
2+ autoantibodies present. Normal blood glucose. No symptoms. Beta cell loss beginning. Can last months to years.
STAGE 2
Presymptomatic — Dysglycaemia
2+ autoantibodies plus abnormal glucose tolerance. No symptoms yet. Significant beta cell loss. Risk of clinical disease ~75% within 5 years.
STAGE 3
Clinical Diabetes
Symptomatic hyperglycaemia. Meets diagnostic criteria. Requires immediate insulin therapy.
Teplizumab (Tzield) — the first approved drug to delay Stage 3 T1D in high-risk individuals. A 14-day course can delay onset by ~2 years in Stage 2 patients.
04 — Insulin Therapy
Insulin: The Cornerstone of Treatment
Discovered in 1921 by Banting & Best, insulin remains the only treatment that sustains life in T1D. Modern therapy uses multiple insulin types to mimic the pancreas's natural pattern.
INSULIN TYPE
ONSET
PEAK
DURATION
EXAMPLES
USE
Ultra-rapid acting
2–5 min
30–90 min
2–4 hrs
Fiasp, Lyumjev
Meals / corrections
Rapid acting
10–20 min
1–3 hrs
3–5 hrs
NovoRapid, Humalog, Apidra
Meals / corrections
Short acting
30–60 min
2–4 hrs
5–8 hrs
Actrapid, Humulin S
Meals (older regimens)
Intermediate acting
1–2 hrs
4–8 hrs
12–18 hrs
Insulatard, Humulin I (NPH)
Background (older)
Long acting
1–2 hrs
Minimal
18–24 hrs
Lantus, Levemir
Basal (background)
Ultra-long acting
1–6 hrs
Minimal
42+ hrs
Tresiba (degludec)
Basal (stable, flexible)
Biosimilars
Varies
Varies
Varies
Semglee, Rezvoglar
Lower-cost alternatives
Basal-Bolus Regimen
The gold standard insulin regimen for T1D. Mimics the pancreas by providing two types of coverage:
◆ Basal insulin: Long or ultra-long acting insulin given once or twice daily. Provides steady background insulin to manage overnight and fasting glucose.
◆ Bolus insulin: Rapid or ultra-rapid acting insulin given at mealtimes. Covers carbohydrate intake and corrects high glucose levels.
◆ Correction doses: Extra rapid-acting insulin calculated using an insulin sensitivity factor (ISF) to bring high glucose back to target.
◆ Insulin-to-carb ratios (ICR): Units of insulin per gram of carbohydrate consumed — personalised for each individual.
Basal-Bolus Regimen
💉 Insulin Pen (MDI)
Multiple daily injections using reusable or disposable pens. Flexible, portable, and widely used. Now available as smart pens with dose tracking.
⚙️ Insulin Pump (CSII)
Continuous subcutaneous infusion via a small wearable device. Delivers programmable basal rates and boluses. Forms the basis of closed-loop systems.
🫁 Inhaled Insulin
Afrezza — an ultra-rapid inhaled insulin for bolus use. Convenient alternative for those who prefer to avoid injections; not suitable for everyone.
05 — Blood Glucose Monitoring
Knowing Your Numbers
Regular glucose monitoring is fundamental to safe T1D management. Technology has transformed this from painful finger-prick testing to painless, continuous, real-time data.
Traditional
Self-Monitoring (SMBG)
Finger-prick blood glucose meter. The original monitoring method, still used for calibration and spot-checks.
◆ Immediate, accurate glucose reading
◆ Inexpensive devices; strips available on prescription
◆ Requires multiple daily finger-pricks
◆ No trend data or alerts
◆ Essential for calibrating some CGM devices
Emerging
Implantable CGM
Long-duration sensors implanted under the skin, lasting months rather than days. Aimed at reducing sensor burden.
◆Eversense 365 — 1-year implantable CGM (US-approved)
◆Inserted by clinician; transmitter worn on skin
◆Eliminates daily/weekly sensor changes
◆Can vibrate directly on body for alerts
◆Reduces waste significantly vs disposable sensors
Widely Used
Flash / FreeStyle Libre (FGM)
A sensor worn on the upper arm scanned by phone or reader for glucose readings. No finger-pricks needed for routine checks.
◆ Libre 2 & 3 offer real-time alerts on low/high glucose
◆ 14-day wear sensor (Libre 2) / up to 15 days (Libre 3)
◆ Libre 3 has 1-minute readings sent continuously to phone
◆ Free on NHS for T1D patients in England
◆ Reads interstitial glucose (slight lag vs blood glucose)
Gold Standard
Continuous Glucose Monitor (CGM)
Real-time continuous monitoring with trend arrows, alarms, and remote sharing. The cornerstone of modern T1D management.
◆ Dexcom G7 — 10-day wear, 5-min readings, very accurate
◆ Dexcom One+ — NHS-funded option in the UK
◆ Medtronic Guardian 4 — integrated with MiniMed pumps
◆ Continuous alerts for hypo & hyperglycaemia
◆ Trend arrows show glucose direction and rate of change
◆ Share data with carers, parents, and clinicians
Time in Range (TIR) — The Key Metric
Modern T1D management focuses on Time in Range — the percentage of time glucose remains within the target range of 3.9–10.0 mmol/L (70–180 mg/dL).
>70%
Time in Range Target
<4%
Time Below Range (<3.9)
<25%
Time Above Range (>10.0)
<53
HbA1c Target (mmol/mol)
06 — Advanced Technology
The Technology Revolution in T1D
The past decade has seen extraordinary advances in diabetes technology, with closed-loop systems now offering near-automated glucose control that was unimaginable just years ago.
Current Standard
Hybrid Closed-Loop (HCL)
The "artificial pancreas." An algorithm automatically adjusts insulin delivery based on CGM readings — requiring only meal announcements from the user.
-
CamAPS FX — Cambridge algorithm (UK); highly adaptive
-
Available on the NHS for under-18s; expanding to adults
-
Tandem Control-IQ — Auto-corrects and suspends; FDA/CE approved
-
Medtronic MiniMed 780G — Auto-correction boluses; 5.5 mmol/L target
-
Omnipod 5 — Tubeless patch pump; SmartAdjust algorithm
-
Studies show significant TIR improvement vs MDI
Established
Predictive Low Glucose Suspend (PLGS)
Pumps that automatically suspend insulin delivery when CGM predicts hypoglycaemia is imminent — a crucial safety feature.
-
Medtronic SmartGuard / Suspend on Low / Suspend Before Low
-
Tandem Basal-IQ technology
-
Significantly reduces nocturnal hypoglycaemia
-
A major step towards closed-loop
-
Now largely superseded by full HCL in many patients
DIY / Open Source
Open-Source APS (OpenAPS)
Community-developed closed-loop systems built by people with diabetes. Pioneered the field and still offer highly customisable options.
-
Loop (iOS) — Compatible Omnipod/Medtronic pumps + Dexcom CGM
-
AndroidAPS (AAPS) — Highly configurable; Android phone
-
OpenAPS — Original DIY system; superseded by Loop/AAPS
-
iAPS/Trio — Advanced forks; Oref1 & SMB algorithms
-
Not officially approved — Used "off-label" with informed consent
-
Community support — Forums and social media
Innovation
Smart Pens & Decision Support
Connected insulin pens bring data tracking and dosing guidance to MDI users — helping those not on pumps optimise their therapy.
-
InPen (Medtronic) — Bluetooth smart pen; dose tracking, bolus calculator
-
NovoPen 6 & Echo Plus — Built-in NFC dose memory; syncs with Libre
-
Bigfoot Unity — Smart pen cap system; automated dosing guidance
-
Reduces insulin stacking and missed doses
-
Integrates with apps like LibreView and Glooko
Emerging
Fully Closed-Loop (FCL)
The next frontier — systems that require no meal announcements, delivering truly automated insulin management 24/7.
-
In clinical trials showing impressive TIR results (~80%+)
-
CamAPS FX moving towards FCL capability
-
Beta Bionics iLet Bionic Pancreas — FDA approved; meal-size agnostic
-
Requires more sophisticated algorithms to handle meals without input
-
Bihormonal systems (insulin + glucagon) also in development
Future
AI & Digital Health Tools
Artificial intelligence is transforming T1D management through pattern recognition, predictive modelling, and personalised insulin dosing recommendations.
-
Glooko / LibreView — Aggregated data analysis for clinicians
-
AI-powered meal recognition via photo (bolus apps)
-
Predictive hypoglycaemia models using ML
-
Remote monitoring platforms for clinical teams
-
Digital therapeutics for T1D education (eg. One Drop)
07 — Holistic Management
Living Well with T1D
T1D management extends far beyond insulin and glucose monitoring. Diet, exercise, mental health, and education are all vital components of optimal care.
🥗
Nutrition
No single diet is prescribed for T1D. The focus is on carbohydrate awareness for accurate bolusing. Low-carb, Mediterranean, and flexible approaches all work when managed well.
-
Carbohydrate counting for meal bolusing
-
Understanding glycaemic index (GI) and glycaemic load (GL)
-
Fibre, fat, and protein also affect blood glucose levels
-
Alcohol can cause delayed hypoglycaemia
📚
Structured Education
Evidence-based education programmes are proven to improve outcomes, confidence, and quality of life.
-
DAFNE — Dose Adjustment For Normal Eating (UK)
-
BERTIE — Online flexible eating programme
-
Pump training programmes (e.g., DAFNE+)
-
Peer support networks and Type 1 diabetes communities
🏃
Exercise
Exercise is highly beneficial but requires careful glucose management. Different exercise types have opposing effects on blood glucose.
-
Aerobic exercise typically lowers blood glucose
-
Anaerobic exercise and HIIT can raise blood glucose acutely
-
Reduce basal insulin before prolonged physical activity (when appropriate)
-
Increased risk of nocturnal hypoglycaemia after exercise
🩺
Routine Screenings
Regular screening for complications and associated conditions is essential.
-
Annual HbA1c, eGFR, and ACR (kidney function)
-
Annual retinal eye screening
-
Annual foot examination (neuropathy assessment)
-
Annual blood pressure, cholesterol, and thyroid assessment
-
Coeliac antibody screening
🧠
Mental Health
T1D carries significant psychological burden. Diabetes distress, burnout, and depression are common and deserve the same attention as physical management.
-
Diabetes distress affects approximately 40% of people with Type 1 diabetes
-
Disordered eating (diabulimia) is a serious risk
-
Fear of hypoglycaemia is extremely common
-
Structured education helps reduce diabetes burnout
💉
Adjunct Medications
Evidence-based education programmes are proven to improve outcomes, confidence, and quality of life.
-
SGLT2 inhibitors (e.g., dapagliflozin) — may reduce glucose levels and cardiovascular risk in carefully selected adults with Type 1 diabetes
-
GLP-1 receptor agonists — used off-label for weight management in some patients
-
Metformin — insulin-sensitising medication used in selected adults
-
Statins — for cardiovascular risk reduction
Managing Hypoglycaemia
Hypoglycaemia ("a hypo") — blood glucose below 3.9 mmol/L (70 mg/dL) — is the most immediate risk in T1D. All people with T1D and their close contacts should know how to recognise and treat it.
🍬 The 15-15 Rule (Mild-Moderate Hypo)
-
Confirm with CGM or meter
-
Take 15–20g fast-acting carbohydrates (5 glucose tablets, 150ml fruit juice, glucose gel)
-
Wait 15 minutes; recheck glucose
-
Repeat if still below 4.0 mmol/L
-
Follow with a slow-release carbohydrate snack
💉 Severe Hypoglycaemia (Unconscious)
If the person cannot swallow or is unconscious:
-
Do NOT give anything by mouth
-
Administer glucagon: GlucaGen kit (IM), Baqsimi (nasal), or Zegalogue (SC)
-
Call 999 immediately
-
Place in recovery position
-
Inform the diabetes team after recovery
08 — Complications
Long-Term Complications
Sustained high blood glucose over years damages blood vessels and nerves throughout the body. Good glycaemic control dramatically reduces — but does not eliminate — this risk. Early screening and intervention are key.
👁️ Diabetic Retinopathy
Damage to retinal blood vessels — the leading cause of preventable blindness in working age. Ranges from mild background changes to proliferative disease requiring laser or injection treatment. Annual screening is essential.
🫘 Diabetic Nephropathy
Progressive kidney damage. Early sign: raised urine albumin-creatinine ratio (ACR). Can progress to chronic kidney disease and end-stage renal failure requiring dialysis or transplant. ACE inhibitors or ARBs are protective.
⚡ Diabetic Neuropathy
Nerve damage affecting extremities (peripheral), autonomic functions (cardiovascular, digestive, sexual), and cranial nerves. Symptoms include numbness, tingling, pain, gastroparesis, and postural hypotension.
❤️ Cardiovascular Disease
People with T1D have 2–10x higher risk of heart attack and stroke. Statin therapy, blood pressure control, and smoking cessation are key preventive strategies alongside glucose management.
🦶 Diabetic Foot Disease
Neuropathy reduces sensation; peripheral arterial disease impairs healing. Minor injuries can escalate to ulceration and, in worst cases, amputation. Daily foot care and annual screening are essential.
🧠 Associated Conditions
T1D is associated with higher rates of other autoimmune conditions including thyroid disease (Hashimoto's, Graves'), coeliac disease, Addison's, and vitiligo. Screening for these is part of routine T1D care.
09 — T1D Across Life Stages
T1D Through Life
T1D management extends far beyond insulin and glucose monitoring. Diet, exercise, mental health, and education are all vital components of optimal care.
👶
Children & Adolescents
T1D is one of the most common chronic conditions in childhood. Management involves the whole family. HCL systems are now NHS-funded for all under-18s in England. Transition to adult services at ~18 is a high-risk period requiring careful support.
🎓
Young Adults
Alcohol, irregular meals, university life, and early careers create unique challenges. This age group has some of the poorest HbA1c levels and highest DKA admission rates. Peer support and flexible technology are especially valuable.
🤰
Pregnancy
Pre-conception planning is critical. Tight glucose control before and during pregnancy reduces the risk of miscarriage, congenital anomalies, and neonatal complications. HCL is recommended in pregnancy (CamAPS FX has a specific pregnancy mode). Folic acid 5mg daily is recommended pre-conception.
👴
Older Adults
Hypoglycaemia risk increases with age due to impaired awareness and renal function. Targets should be individualised. Cognitive impairment, falls risk, and polypharmacy require careful consideration in management decisions.
10 — The Future of T1D
Research, Cures & What's Coming
Research into T1D is accelerating rapidly. From immune therapies that delay or prevent the disease to beta cell replacement and gene therapy, the next decade promises transformative developments.
Approved 2022
Teplizumab (Tzield)
The first therapy to delay the onset of T1D. An anti-CD3 monoclonal antibody that modulates the immune response.
-
14-day IV infusion course for Stage 2 Type 1 diabetes
-
Delays clinical onset by a median of more than 2 years
-
FDA approved; available in the United States; under review in the UK and EU
-
PROTECT trial showed benefit in newly diagnosed Type 1 diabetes
-
Represents a paradigm shift in Type 1 diabetes prevention
Research Phase
Gene Therapy & Gene Editing
Editing genes to protect beta cells from autoimmune attack or to engineer other cell types to produce insulin.
-
CRISPR-based approaches to engineer immune tolerance
-
Gene editing to enable insulin production in liver or gut cells
-
Early preclinical and first-in-human studies are underway
-
Long-term goal: combine gene editing with stem cell therapy
In Development
Immune Therapies
Multiple immunotherapy approaches targeting different stages of the autoimmune process to prevent, halt or reverse T1D.
-
Anti-thymocyte globulin (ATG) — preserves C-peptide in new-onset Type 1 diabetes
-
Abatacept — CTLA-4 Ig; preserves beta cell function
-
Anti-CD20 (rituximab) — B-cell depletion therapy
-
GAD-alum (Diamyd) vaccine — antigen-specific immunotherapy
-
Combination immunotherapy trials are ongoing
Horizon
Smart Insulin & Glucose-Responsive Insulin
"Smart" insulins that automatically activate only when glucose rises and shut off when glucose normalises — eliminating hypoglycaemia risk.
-
NNC2215 (Novo Nordisk) — glucose-responsive insulin in Phase 2 clinical trials
-
Could significantly reduce or eliminate hypoglycaemia associated with insulin therapy
-
Long-acting depot formulations for weekly or monthly dosing
-
Major focus of insulin pharmaceutical research
Clinical Trials
Beta Cell Replacement
Replacing destroyed beta cells with new insulin-producing cells — a potential functional cure for T1D.
-
Islet transplantation — established treatment requiring lifelong immunosuppression
-
Vertex VX-880 — stem cell-derived beta cells with promising early trial results (2023–2024)
-
Encapsulation technology — devices that protect transplanted cells from immune attack and may eliminate the need for immunosuppression
-
Sernova Cell Pouch — implantable scaffold for islet transplantation
-
Long-term goal: eliminate the need for insulin injections entirely
Available Now
Fully Automated Insulin Delivery
The progression from current hybrid closed-loop to truly fully automated 24/7 insulin delivery — removing the cognitive burden from people with T1D entirely.
-
Beta Bionics iLet — requires only meal-size announcements; now FDA approved
-
CamAPS FX — fully closed-loop mode in development
-
Next-generation miniaturised all-in-one patch devices
-
Integration with smartwatches for seamless glucose monitoring
-
Neural network algorithms that continuously personalise insulin delivery to each user
T1D Screening Programmes
Population-wide screening for T1D autoantibodies is being piloted in several countries, aiming to identify children at Stage 1 or 2 before clinical diagnosis — enabling preventive therapy and preventing DKA at diagnosis. The ELSA programme (NHS England) and Germany's Fr1da study are leading examples of this approach.
11 — Support & Resources
Getting Support
Living with T1D is a 24/7 responsibility. No one should face it alone. These organisations and resources provide vital support, advocacy, and information.
JDRF UK
The leading T1D charity funding research and providing support. jdrf.org.uk
Diabetes UK
National diabetes charity with helpline, local groups and evidence-based resources. diabetes.org.uk
T1D Online Communities
TypeOneNation (JDRF), Beyond Type 1, TuDiabetes, and active Facebook/Reddit groups offering peer support.
Looped / OpenAPS
Open-source DIY closed-loop community on Facebook and Discord. Huge wealth of practical knowledge for tech-savvy T1Ds.
Important: This guide is for informational purposes only. It is not a substitute for professional medical advice. Always consult your diabetes care team — including your diabetologist, diabetes specialist nurse, and dietitian — for personalised management decisions.